人体临床Ⅱ、Ⅲ期试验结果证实,应用具有高结合特异性的人源性抗IgE抗体治疗支气管哮喘和过敏性鼻炎是可行的。该治疗不仅可中和游离的IgE和抑制B细胞合成分泌IgE,而且可以抑制IgE-抗IgE抗体免疫复合体的聚集以及下调嗜碱粒细胞和肥大细胞上高亲和力Fc段受体(FαRI)。本文对抗IgE抗体产生特异性的结构基础以及体外实验、动物实验和人体临床试验的相关数据进行了分析,试图提供一个具有说服力的药理学解释来阐明在短期和长期治疗中抗IgE抗体治疗的作用。 Human clinical Ⅱ, Ⅲ phase test results confirmed that the use of high binding specificity of human anti-IgE antibodies in the treatment of bronchial asthma and allergic rhinitis is feasible. This treatment not only neutralizes free IgE and inhibits the synthesis and secretion of IgE by B cells, but also inhibits the aggregation of IgE-anti-IgE antibody immune complexes and down-regulates high-affinity Fc receptor (FαRI) on basophils and mast cells. In this review, we analyze the structural basis of anti-IgE antibodies and the data from in vitro, animal and human clinical trials in an effort to provide a persuasive pharmacological explanation for the use of anti-IgE antibodies in short and long term treatment effect.